Oct 11, 2019

FDA approves another new migraine medicine

Eli Lilly has two prominent migraine drugs now. Photo: Igor Golovniov/SOPA Images/LightRocket via Getty Images

The Food and Drug Administration has approved Reyvow, a new pill made by Eli Lilly that treats migraine attacks. The drugmaker did not immediately disclose the drug's price.

The big picture: Reyvow is not approved for the prevention of migraines, but other new drugs on the market — Aimovig, Ajovy and Emgality — are described as preventative for migraines.

Go deeper

A drug pricing method that values the price of a life gets new attention

Illustration: Eniola Odetunde/Axios

A drug pricing model used by other countries but long opposed by drugmakers in the U.S. is getting new attention amid the political debate over drug prices, the Wall Street Journal reports.

How it works: The method, pushed by the Institute for Clinical and Economic Review, "puts a dollar figure on a year of healthy life, calculates how much health a drug restores to a sick patient, then prices drugs accordingly," per the Journal.

Go deeperArrowNov 5, 2019

New drugs are launching with ever-higher prices

Illustration: Eniola Odetunde/Axios

The average launch prices for new brand-name drugs have skyrocketed over the past decade, according to an analysis from drug research firm 46brooklyn.

Why it matters: The U.S. prescription drug market increasingly has thrived on high initial price tags and subsequent increases. That has resulted in higher premiums and out-of-pocket costs for new drugs, as well as more expensive generics.

Go deeperArrowOct 16, 2019

Elizabeth Warren's dream health care world

Illustration: Aïda Amer/Axios

Sen. Elizabeth Warren's Medicare for All plan takes on every major health care industry — insurers, doctors, hospitals and drug companies — in her pursuit of expanding coverage and lowering costs for the middle class.

Why it matters: We've never tried any cost containment measures that are remotely close to being as aggressive as Warren's, and there could be consequences if payment rates are slashed so low.

Go deeperArrowNov 4, 2019